OBJECTIVE TEST FOR EARLY PARKINSONS SYNDROME

描述：(申请人摘要)拟议项目的目标是 开发一组测试(PD电池)，可以提供廉价的 客观的帮助，首先，帕金森综合症的早期诊断 (PS)第二，有助于其鉴别诊断，如特发性 帕金森氏病(IPD)；帕金森加综合征(P-Plus)，如 纹状体黑质变性；和特发性震颤 震颤为主的帕金森综合征等。PD电池已经被 在初步研究中，明确区分了正常和 对照(NC)受试者和早期轻度推定IPD患者(95 %的敏感度，94%的特异度和 接收-运算符曲线[ROC]为0.98)。该电池包含以下测试 运动功能、嗅觉和情感状态(即抑郁)。什么时候 对其他NC受试者和IPD患者进行前瞻性研究 以这种方式，测试电池正确地识别了48个NC受试者中的44个和10个 11例IPD患者。此外，9名ET患者中有7名有检测结果 在正常范围内，表明电池可以帮助 震颤为主的IPD与ET的鉴别。 下一步是通过前瞻性测试来验证PD电池 怀疑为PS但诊断不确定的患者( 不确定的PS组)。这些患者将接受PD电池，统一 帕金森病评定量表(UPDRS)在进入研究时。二 几年后，在前后进行了MRI扫描、UPDRS和运动测试 左旋多巴给药将会结束。这些测试应该确定哪些是 这些患者可能变得正常，可能是IPD或可能的P-Plus。 这些评价的结果将与他们从 进入研究时的PD电池。为了进一步验证 电池，更多的NC受试者和患者：1)新诊断和轻度 受累PS；2)P-Plus综合征；3)ET；4)轻度阿尔茨海默病(AD) 5)对具有帕金森氏症特征的AD(AD/PD)进行测试。 如果成功，PD电池可以帮助确保适当的患者接受 适当的护理，从而最大限度地减少医疗费用和残疾。在 未来，PD电池可以使早期或临床前检测到 处于危险中的人。这块电池用于早期检测，再加上未来 神经保护性疗法，可以进一步降低医疗成本和 残疾。此外，测试电池可以在未来用于 协助研究IPD可能的遗传和/或环境原因。

DESCRIPTION: (Applicant's Abstract) The goal of the proposed project is to develop a battery of tests (PD Battery) that could provide an inexpensive and objective aid for, first, the early diagnosis of Parkinson's syndrome (PS) and second, to aid in its differential diagnosis, such as idiopathic Parkinson's disease (iPD); Parkinson-Plus syndromes (P-Plus) such as striato-nigral degeneration; and essential tremor (ET) as distinguished from tremor predominant parkinsonism and others. The PD Battery has been developed that, in preliminary studies, clearly distinguishes between normal control (NC) subjects and patients with early mild presumptive iPD (95 percent sensitivity, 94 percent specificity and the area under the receiver-operator curve [ROC] of 0.98). The battery incorporates tests of motor function, olfaction, and affective state (i.e., depression). When additional NC subjects and iPD patients were studied in a prospective manner, the test battery correctly identified 44 of 48 NC subjects and 10 of the 11 iPD patients. In addition, 7 of 9 patients with ET had test results in the normal range suggesting that the battery can aid in the differentiation of tremor predominant iPD and ET. The next step is to validate the PD Battery by prospectively testing patients in whom PS is suspected but the diagnosis is uncertain (the Uncertain PS group). These patients will undergo the PD Battery, Unified Parkinson Disease Rating Scale (UPDRS) upon entrance into the study. Two years later, a MRI scan and the UPDRS and motor testing before and after levodopa administration will be done. These tests should identify which of these patients become probably normal, probably iPD or Probable P-Plus. Results of these evaluations will be correlated with their results from the PD Battery at time of entrance into the study. To further validate the battery, more NC subjects and patients with: 1) newly diagnosed and mildly affected PS; 2) P-Plus syndromes; 3) ET; 4) mild Alzheimer's disease (AD) and 5) AD with parkinsonian features (AD/PD) will be tested. If successful, the PD Battery could help assure appropriate patients receive appropriate care, thus, minimizing health costs and disability. In the future, the PD Battery could allow early or pre-clinical detection of persons at risk. this battery for early detection, coupled with future neuro-protective therapies, could further reduce health costs and disability. In addition , the test battery could be used in the future to aid research into the possible genetic and/or environmental causes of iPD.